Virtu Financial’s NovoCure NVCR Stock Holding History

Virtu Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,172	Closed	-$222K	–	2057
2025 Q3	$222K	Buy	+17,172	New	+$229K	0.01%	872
2022 Q4	–	Sell	-6,284	Closed	-$477K	–	1984
2022 Q3	$477K	Buy	+6,284	New	+$490K	0.04%	418
2022 Q2	–	Sell	-4,399	Closed	-$364K	–	1918
2022 Q1	$364K	Sell	4,399 -409	-9%	-$30.1K	0.03%	509
2021 Q4	$361K	Buy	+4,808	New	+$483K	0.04%	524
2021 Q3	–	Sell	-5,846	Closed	-$1.3M	–	1821
2021 Q2	$1.3M	Buy	5,846 +2,547	+77%	+$495K	0.13%	133
2021 Q1	$436K	Buy	+3,299	New	+$522K	0.03%	590
2020 Q4	–	Sell	-5,013	Closed	-$558K	–	1683
2020 Q3	$558K	Buy	+5,013	New	+$401K	0.1%	261
2019 Q3	–	Sell	-20,245	Closed	-$1.28M	–	1700
2019 Q2	$1.28M	Buy	+20,245	New	+$1.03M	0.08%	219

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Virtu Financial's NVCR Position: Q4 2025 in Review

Virtu Financial sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 17,172 shares — an estimated $222K sold.

Virtu Financial first reported a position in NVCR in Q2 2019 and held it in 8 quarters. The position peaked at $1.3M in Q2 2021. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Virtu Financial reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Virtu Financial sold 17,172 NovoCure shares in Q4 2025, an estimated $222K.
Virtu Financial first reported a position in NovoCure in Q2 2019 and held it in 8 quarters.
Virtu Financial's NovoCure position peaked at $1.3M in Q2 2021.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.